SCHEMBL16616368

SCHEMBL16616368

CC(C)(C)OC(=O)N1C[C@H]2CN(Cc3ccc(C#N)cc3)C[C@H]2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.50
CYP3A4 P08684 3/20 0.48
CYP2C19 P33261 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
DPP4 P27487 1/20 0.47
DPP8 Q6V1X1 1/20 0.47
KCNK3 O14649 3/20 0.46
KCNK9 Q9NPC2 3/20 0.46
CYP2C9 P11712 2/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2D6 P10635 2/20 0.45
USP2 O75604 2/20 0.44
NR1H2 P55055 1/20 0.44
FAAH O00519 1/20 0.44
AR P10275 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094438 0.88 GPR119 (0.48) GPR119CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL3121813 0.87 GPR119 (0.48) GPR119CYP3A4CYP2C19ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL4667417 0.86 GPR119 (0.47) GPR119CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL21276170 0.85 KCNK3 (0.59) KCNK3KCNK9MEN1KMT2ANR1H2
SCHEMBL25389107 0.84 HDAC1 (0.52) KCNK3KCNK9MEN1KMT2ANR1H2
SCHEMBL23181092 0.84 KCNK3 (0.48) GPR119KCNK3KCNK9NR1H2
SCHEMBL1066770 0.84 CYP3A4 (0.60) GPR119CYP3A4CYP2C19ALDH1A1MAPK1
SCHEMBL16053284 0.84 KCNK3 (0.55) GPR119KCNK3KCNK9NR1H2
SCHEMBL649847 0.84 KCNK3 (0.55) GPR119KCNK3KCNK9NR1H2
SCHEMBL584450 0.84 KCNK3 (0.55) GPR119KCNK3KCNK9NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2822656-B1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE CANCER RES INST ROYAL (GB) 2016-10-19 EP disclosed
EP-2822656-B1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE CANCER RES INST ROYAL (GB) 2016-10-19 EP disclosed
US-9193689-B2 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-11-24 US disclosed
US-9193689-B2 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-11-24 US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 US disclosed
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099732-A1 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE TNKS, TNKS2, PARP11 GPR119 2578/4885CYP3A4 2501/4885CYP2C19 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.